Current immune checkpoint inhibitors (ICI) therapy works by blocking the interaction between programmed death-ligand 1 (PD-L1) on tumor cells and programmed cell death protein 1 (PD-1) on T cells, thereby allowing the T cells to kill tumor cells. Here, PDCD1 is linked to neoplasm.